CluePoints Announces the Shortlist for the Fierce Life Sciences Innovation Awards Finalist List
RBQM Leaders in the field have secured a spot in the finals for the Data Analysis/Business Intelligence category in this prestigious award.
Wayne, Pennsylvania, October 29th ( PRNewswire ) – CluePoints is a leading provider of risk-based quality management ( RBQM ) and clinical data quality monitoring software. The company has been shortlisted in the 2026 Fierce Life Sciences Innovation Awards category for data analysis/business intelligence.
CluePoints This time's shortlisting is due to the new methods it has adopted for clinical data review. This year, based on the statistical methods at the core of its RBQM software, the company has expanded three complementary capabilities: Intelligent Query Detection ( IQD ), Medical , and , Safety Review ( MSR ), and Intelligent Medical Coding ( IMC ). These functions continue to rely on the mature statistical engine and site supervision capabilities that CluePoints has always relied on, and they integrate the previously dispersed data review methods into a connected model.
The CluePoints platform has helped to reduce the risks of thousands of studies and identified over 250,000 potential issues. Building on its ten-year lead in RBQM, IQD, MSR, and IMC ensure that patient safety signals and data compliance gaps are no longer reviewed in isolation.
The company stated that many practices in the industry involve hastily overlaying AI on traditional workflows, whereas CluePoints has chosen a different approach. Its statistical model incorporates AI wherever it can improve outcomes, rather than introducing AI merely to create buzz. All outputs are explainable, auditable, and defensible.
CluePoints Chief Commercial Officer Martin Magazzolo stated: "There is never a lack of data in clinical trials. The problem lies in the fragmented tools and isolated systems, which prevent teams from having the clarity and confidence to act promptly based on data insights. The CluePoints approach enables teams to identify issues earlier, take action more quickly, and provide auditable oversight in a confident manner. We are delighted that this year's Fierce award recognizes our commitment to transforming raw data into actionable intelligence."
Winners of all categories will be announced on November 19, 2026, at the Fierce Vanguard Awards Gala event held at The Lighthouse, located at Pier 61 in New York.
To learn how CluePoints can help transform your clinical data management, please visit www.cluepoints.com.
About CluePoints
CluePoints provides support to pharmaceutical, biotechnology, and contract research organizations with AI's risk-based quality management and clinical data review software. Its solutions help clinical teams to identify emerging risks earlier, focus manual reviews on critical issues, and maintain traceable and auditable oversight throughout the entire product lifecycle. CluePoints combines advanced statistics, machine learning, and deep clinical expertise to support more consistent and informed decision-making within clinical trial portfolios.
